<DOC>
	<DOCNO>NCT01034579</DOCNO>
	<brief_summary>This study , REbif® v Glatiramer acetate relapse multiple sclerosis ( MS ) disease - pharmacogenetic ( ) ( REGARD-PGx ) single blood sample exploratory pharmacogenetic study REGARD trial . The aim trial provide additional data factor influence interferon ( IFN ) beta response . This Phase 4 trial involve subject previously participate REGARD trial . To address trial objective , single visit follow-up trial perform blood sample collect .</brief_summary>
	<brief_title>The REbif® v Glatiramer Acetate Relapsing Multiple Sclerosis Pharmacogenetics Trial</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Was randomize REGARD 24735 study Is willing able comply protocol Has give write informed consent perform trialrelated activity Is unwilling unable participate study Is already include initial REGARD 24735 PGx substudy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Genetic marker</keyword>
</DOC>